On June 20, 2023, Insulet Corporation announced the release of their Omnipod 5 Automated Insulin Delivery System (Omnipod 5) in the United Kingdom. This system is designed for individuals aged two years and older who are living with type 1 diabetes (T1D). Omnipod 5 is the first tubeless hybrid closed loop system to receive a CE mark, and it is capable of integrating with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin delivery and help prevent high and low glucose levels.
The Omnipod 5 system includes a tubeless Pod that has been enhanced with SmartAdjust technology, as well as the Omnipod 5 Controller featuring an integrated SmartBolus Calculator. The system is interoperable with the Dexcom G6 CGM, allowing for automated insulin delivery. What sets Omnipod 5 apart is its ability to adapt with every Pod change, meeting the unique insulin needs of each individual. The system adjusts insulin using a customized Target Glucose, rather than a range.
The Omnipod 5 system is indicated for use by individuals with type 1 diabetes mellitus who are two years of age and older. In a three-month clinical study, three cases of severe hypoglycemia and one case of diabetic ketoacidosis (DKA) were reported in children, adults, and adolescents during Omnipod 5 System use. It is important to note that these cases were not related to automated insulin delivery malfunction.
Podium Corporation (PODD) Stock Performance and Growth in 2023: Health Technology Sector and Medical Specialties Industry
On June 20, 2023, the stock performance of Podium Corporation (PODD) was closely watched by investors and analysts alike. The day’s range was between 281.83 and 290.69, with a volume traded for the day of 28,427. The market cap of Podium Corporation was $19.8B, which was a significant increase from the previous year. The earnings growth for the current year was a staggering +2,020.26%, which was a positive sign for the company. The revenue growth for the last year was +18.79%, which was a good sign for the company. The next reporting date for the company was August 3, 2023, and the EPS forecast for this quarter was $0.26. Podium Corporation operates in the health technology sector and the medical specialties industry.
Insulet Corp (PODD) Stock Forecast: Analysts Predict a 23% Increase in Target Price
Insulet Corp (PODD) is a medical device company that specializes in the development and manufacturing of insulin pumps and other diabetes management products. As of June 20, 2023, the company’s stock was trading at $288.74 per share. However, according to the 18 analysts offering 12-month price forecasts for Insulet Corp, the median target price for the stock is $355.00, with a high estimate of $395.00 and a low estimate of $329.00.
The consensus among 20 polled investment analysts is to buy stock in Insulet Corp. This rating has held steady since June, when it was unchanged from a buy rating. This indicates that investors are optimistic about the company’s future prospects and believe that its stock price will rise in the coming months.
In terms of financial performance, Insulet Corp reported earnings per share of $0.26 and sales of $386.1 million for the current quarter. The company is set to report its earnings on August 3, 2023, and investors will be closely watching the results to see if the company meets or exceeds expectations.
Overall, the outlook for Insulet Corp’s stock performance is positive. The company has a strong consensus rating among investment analysts, and its median target price represents a potential increase of almost 23% from the current price. Investors will be eagerly awaiting the company’s upcoming earnings report to see if it can continue to deliver strong financial results.
The post Insulet Corporation Releases Omnipod 5 Automated Insulin Delivery System in the UK appeared first on Best Stocks.
